FDA Eases Animal Tests for Life-Saving Antibody Drugs
Published Date: 12/3/2025
Notice
Summary
The FDA just dropped a draft guide to make safety testing for certain monoclonal antibodies faster and kinder to animals. If you’re a drug developer, this means fewer long tests and less use of primates, saving time and money. Get your comments in by February 2, 2026, to help shape the final rules!
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Shorter or Skipped Long Toxicology Tests
If you are a drug developer, FDA's draft guidance says general animal toxicology studies for monospecific monoclonal antibodies may not be needed or may be limited to a short-term study. The guidance gives examples when a 3-month or longer animal toxicology study may not be warranted. Submit comments by February 2, 2026 if you want the Agency to consider your input.
Use of Weight-of-Evidence and New Methods
If you develop monoclonal antibodies, the draft guidance allows replacing certain animal safety studies with a weight-of-evidence (WoE) risk assessment. The guidance says a WoE assessment may include new approach methodologies as alternatives to some animal testing.
Changes to Reproductive & Juvenile Testing
The draft guidance provides recommendations on reproductive, developmental, and juvenile toxicity assessments for monospecific monoclonal antibodies. If finalized, those recommendations could change when and what kinds of reproductive or juvenile animal studies sponsors must do.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17659, Rahim Shafa; Denial of Hearing; Final Debarment Order
The Food and Drug Administration (FDA or Agency) is denying a request for a hearing submitted by Rahim Shafa (Dr. Shafa) and is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Dr. Shafa from providing services in any capacity to a person that has an approved or pending drug product application and debarring Dr. Shafa for 20 years from importing or offering for import any drug into the United States. FDA bases this order on the findings that Dr. Shafa was convicted of multiple felonies under Federal law that relate to the regulation of any drug product under the FD&C Act and the importation into the United States of any drug or controlled substance under the FD&C Act. FDA provided notice to Dr. Shafa of the proposed debarment and an opportunity to request a hearing. Dr. Shafa submitted a request for a hearing but failed to file with the Agency information and analyses sufficient to create a basis for a hearing.
2026-17676, Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and Cosmetic Act and Associated Fees
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection pertaining to the registration of human drug compounding outsourcing facilities under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and associated fees.
2026-17598, Agency Information Collection Activities; Proposed Collection; Comment Request; Focus Groups and Interviews as Used by the Food and Drug Administration
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the generic collection of focus group information as used by FDA for all FDA-regulated products.
Previous / Next Documents
Previous: 2025-21863, Agency Information Collection Extension
The Department of Energy is asking to keep collecting feedback from customers and stakeholders for three more years to help improve their services. They want your thoughts on how useful and easy this feedback process is, and you have until February 2, 2026, to share your ideas. This extension won’t cost extra money but aims to make the agency’s work better and smoother for everyone involved.
Next: 2025-21865, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding a closed virtual meeting on January 6, 2026, to review important grant applications about social and environmental health topics. These meetings are private to protect sensitive information and personal privacy. Researchers applying for grants and NIH staff are the main people involved, with no new costs or deadlines announced.